Cartesian Therapeutics plunges on massive $5.02 EPS miss, revenue collapse
Biotech's revenue falls 93% year-over-year to $2.8M amid collaboration shortfall, net loss widens to $130.3M
Cartesian Therapeutics shares tumbled Tuesday after the clinical-stage biotechnology company reported a massive earnings miss for full-year 2025, with losses far exceeding analyst expectations and revenue collapsing 93% from the prior year.
The company posted a loss per share of $5.02 for 2025, dramatically missing analyst expectations of a $0.63 loss—a 697% shortfall that underscores the challenges facing the Watertown, Massachusetts-based biotech. While revenue of $2.8 million technically beat the $0.2 million consensus estimate, the figure represents a steep decline from $38.9 million in 2024, driven entirely by sharply lower collaboration revenue.
Cartesian's net loss widened substantially to $130.3 million from $77.4 million in the prior year, reflecting heavy investment in clinical programs amid the revenue shortfall. The company reported a cash position of $126.9 million, which management stated will fund operations into mid-2027, including completion of the ongoing Phase 3 AURORA trial of its lead asset Descartes-08.
Notably absent from the announcement was any financial guidance for 2026, leaving investors without clear visibility on the company's path to profitability or future revenue streams. The lack of forward-looking guidance comes at a critical juncture for Cartesian, which is executing on its pivotal Phase 3 trial for Descartes-08 in generalized myasthenia gravis, a debilitating autoimmune disorder.
Descartes-08 is an autologous mRNA CAR-T cell therapy targeting B cell maturation antigen (BCMA), designed to be administered without the need for preconditioning chemotherapy—a key differentiator from traditional CAR-T approaches. The AURORA trial, which received Special Protocol Assessment agreement from the FDA in January 2025, is enrolling 100 patients in a 1:1 randomized study against placebo, with primary endpoint data expected in 2027.
Despite the disappointing earnings results, analysts maintain a "Moderate Buy" consensus on Cartesian shares, with an average price target of $38.50—representing substantial upside from current trading levels around $6.85. The stock has already declined sharply from its 52-week high of $18.80, reflecting investor concerns about the company's cash burn and clinical execution risk.
The dramatic revenue decline appears tied to the conclusion or reduction of collaboration agreements that provided substantial funding in 2024, leaving Cartesian more reliant on its cash reserves to advance clinical programs. While the company has sufficient liquidity to reach its key data readouts, the absence of non-dilutive funding sources increases the likelihood of future capital raises that could dilute existing shareholders.
Beyond the AURORA trial, Cartesian is advancing a Phase 2 TRITON study of Descartes-08 in dermatomyositis, scheduled to initiate in the first half of 2026. The company also plans a pediatric HELIOS trial in juvenile dermatomyositis, for which Descartes-08 has received Rare Pediatric Disease Designation from the FDA.
Cartesian's path forward hinges entirely on clinical execution and the ability to demonstrate compelling efficacy and safety data from its Phase 3 program. The company's balance sheet, while currently adequate, will face increasing pressure as it advances multiple trials toward data readouts, making cash management and potential strategic partnerships critical considerations for management.
Investors will be watching closely for any updates on enrollment progress in the AURORA trial and potential interim data analyses that could provide early insight into Descartes-08's therapeutic potential. With the stock trading near its 52-week lows and the company's primary catalyst still more than a year away, Cartesian faces a challenging period of maintaining investor confidence while executing on its clinical strategy.